Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas

Abstract

CAR T-cells have transformed the therapeutic landscape for patients with relapsed/refractory aggressive B-cell lymphomas. Currently, three CAR T-cell products are approved or soon to be approved: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. These products differ in construct, manufacturing, clinical trial design and toxicity profile. Patient selection for CAR T-cells, and the ideal product for a given patient, involves myriad considerations including age, fitness, prior therapies, comorbid diseases, organ function, logistics of administration, turnaround time, and institutional familiarity. This article reviews the proper patient and product selection for the management of patients with relapsed/refractory aggressive B-cell lymphomas.

Keywords:

• Cellular immunotherapy
• CAR T-cells
• non-Hodgkin lymphoma
• diffuse
• large B-cell lymphoma
• high-grade B-cell lymphoma

Disclosure statement

JSA reports consulting for Allogene, Celgene, Juno Therapeutics, Kite Pharma and Novartis. PCJ reports no disclosures.